Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Basic): 2021-2025

Historic EPS (Basic) for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $0.50.

  • SAB Biotherapeutics' EPS (Basic) rose 144.64% to $0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 62.22%. This contributed to the annual value of -$3.68 for FY2024, which is 51.83% up from last year.
  • Per SAB Biotherapeutics' latest filing, its EPS (Basic) stood at $0.50 for Q3 2025, which was up 145.87% from -$1.09 recorded in Q2 2025.
  • SAB Biotherapeutics' EPS (Basic)'s 5-year high stood at $0.50 during Q3 2025, with a 5-year trough of -$3.85 in Q4 2023.
  • For the 3-year period, SAB Biotherapeutics' EPS (Basic) averaged around -$1.13, with its median value being -$1.09 (2025).
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 7,400.00% in 2023, then spiked by 144.64% in 2025.
  • SAB Biotherapeutics' EPS (Basic) (Quarterly) stood at -$0.41 in 2021, then soared by 56.10% to -$0.18 in 2022, then slumped by 2,038.89% to -$3.85 in 2023, then skyrocketed by 68.05% to -$1.23 in 2024, then skyrocketed by 144.64% to $0.50 in 2025.
  • Its last three reported values are $0.50 in Q3 2025, -$1.09 for Q2 2025, and -$0.56 during Q1 2025.